

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/800,022		
Filing Date	March 12, 2004		
First Named Inventor	Frederick F. VanGoor		
Group Art Unit	1614 626		
Examiner Name	Not Yet Assigned Joseph Kasa		
Attorney Docket Number	VPI/03-103 US		

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials			n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
JK	B1	wo	00/07996	Chiron Corporation	17 February 2000		
JK	B2	wo	03/084544	CV Therapeutics, Inc.	16 October 2003		
JK	В3	DE	41 26 543	Chem. & Pharm. Patent Hold Ltd.	11 February 1993		
JK	B4	FR	2.104.932	Ferlux	28 April 1972		
	<u> </u>	ļ					
		1				1	

OTHER NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
JK	CI	Nargund, et al., "Synthesis and Anti-inflammatory Activity of Fluorinated Phenyl Styryl Ketones and N-Phenyl-5-substituted Aryl-3-p-(fluorophenyl) Pyrazolins and Pyrazoles", Journal of Pharm. Sciences, Am. Pharm. Association, Vol 81, No. 9, Pages 892-894, Sept. 1992.			
した	C2	Nair, et al. "Synthesis & Reactions of 1-(2-Furyl)-3-(substituted-2-hydroxyphenyl)propanediones", Indian J. Chem., Vol. 21, Pages 573-574, 1982			
JK	C3	Database Chemcats, Zelinski Inst. Of Organic Chemistry, Moscow, XP-002288253, 2003			

* a copy of this reference is not provided	as it was previously cited by or submitted to the office in a prior application,
U.S.S.N, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,
continuation-in-part, and divisional applie	cations).

Examiner Signature	Kosack	Date Considered	2-10-0Ce
-----------------------	--------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.